 Donna Curtis
Concepts (148)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Influenza A Virus, H1N1 Subtype | 6 | 2016 | 140 | 1.010 |
Why?
| | Influenza Vaccines | 3 | 2016 | 500 | 0.840 |
Why?
| | Influenza, Human | 7 | 2016 | 554 | 0.760 |
Why?
| | Immunocompromised Host | 2 | 2019 | 200 | 0.640 |
Why?
| | Orthomyxoviridae | 2 | 2015 | 37 | 0.550 |
Why?
| | West Nile Fever | 1 | 2016 | 51 | 0.540 |
Why?
| | Virus Shedding | 1 | 2015 | 41 | 0.530 |
Why?
| | Antibodies, Viral | 2 | 2016 | 542 | 0.510 |
Why?
| | B-Lymphocyte Subsets | 1 | 2015 | 66 | 0.500 |
Why?
| | Vaccination | 5 | 2020 | 1222 | 0.450 |
Why?
| | Vaccines, Attenuated | 3 | 2020 | 114 | 0.450 |
Why?
| | HIV Infections | 2 | 2015 | 2459 | 0.380 |
Why?
| | Kidney Transplantation | 1 | 2016 | 585 | 0.360 |
Why?
| | Hematopoietic Stem Cell Transplantation | 3 | 2021 | 540 | 0.340 |
Why?
| | Postoperative Complications | 2 | 2016 | 2235 | 0.320 |
Why?
| | Hemagglutination Inhibition Tests | 3 | 2016 | 37 | 0.300 |
Why?
| | Organ Transplantation | 2 | 2019 | 165 | 0.290 |
Why?
| | Cross Infection | 2 | 2019 | 205 | 0.270 |
Why?
| | Child | 18 | 2023 | 19129 | 0.260 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 2 | 2017 | 190 | 0.250 |
Why?
| | Respiratory Tract Infections | 2 | 2022 | 331 | 0.250 |
Why?
| | Intensive Care Units | 3 | 2017 | 635 | 0.240 |
Why?
| | Child, Preschool | 9 | 2019 | 9491 | 0.230 |
Why?
| | Staphylococcal Infections | 2 | 2017 | 346 | 0.220 |
Why?
| | Hospitalization | 4 | 2019 | 1784 | 0.220 |
Why?
| | Liver Transplantation | 2 | 2020 | 847 | 0.220 |
Why?
| | Enterovirus Infections | 2 | 2016 | 164 | 0.210 |
Why?
| | Primary Graft Dysfunction | 1 | 2020 | 32 | 0.180 |
Why?
| | Laboratories | 1 | 2021 | 97 | 0.180 |
Why?
| | Pediatrics | 2 | 2019 | 985 | 0.180 |
Why?
| | Carrier State | 2 | 2017 | 57 | 0.180 |
Why?
| | Opportunistic Infections | 1 | 2019 | 42 | 0.170 |
Why?
| | Pneumococcal Vaccines | 1 | 2021 | 140 | 0.170 |
Why?
| | Advisory Committees | 1 | 2020 | 212 | 0.170 |
Why?
| | Infection Control | 2 | 2017 | 135 | 0.170 |
Why?
| | Communicable Diseases | 1 | 2021 | 132 | 0.170 |
Why?
| | Postoperative Care | 1 | 2020 | 237 | 0.170 |
Why?
| | Transplant Recipients | 1 | 2020 | 148 | 0.170 |
Why?
| | Respiration, Artificial | 1 | 2022 | 545 | 0.170 |
Why?
| | Mucositis | 1 | 2018 | 20 | 0.160 |
Why?
| | Hospital Costs | 1 | 2019 | 110 | 0.160 |
Why?
| | Adolescent | 8 | 2019 | 18479 | 0.160 |
Why?
| | Triazoles | 1 | 2018 | 134 | 0.150 |
Why?
| | Cytomegalovirus Retinitis | 1 | 2016 | 13 | 0.150 |
Why?
| | Societies, Medical | 1 | 2020 | 703 | 0.140 |
Why?
| | Vaccines, Inactivated | 1 | 2016 | 68 | 0.140 |
Why?
| | Costs and Cost Analysis | 1 | 2017 | 202 | 0.140 |
Why?
| | Graft vs Host Disease | 1 | 2018 | 216 | 0.140 |
Why?
| | Polymerase Chain Reaction | 2 | 2016 | 1012 | 0.140 |
Why?
| | Cytomegalovirus | 1 | 2016 | 144 | 0.130 |
Why?
| | Humans | 24 | 2023 | 118983 | 0.130 |
Why?
| | Nasopharynx | 1 | 2015 | 64 | 0.130 |
Why?
| | Enterovirus D, Human | 1 | 2016 | 76 | 0.130 |
Why?
| | Immunosuppressive Agents | 1 | 2019 | 681 | 0.130 |
Why?
| | Male | 14 | 2019 | 57808 | 0.130 |
Why?
| | Colorado | 7 | 2021 | 4196 | 0.130 |
Why?
| | DNA, Viral | 1 | 2016 | 356 | 0.120 |
Why?
| | Retrospective Studies | 11 | 2022 | 12977 | 0.120 |
Why?
| | Immunoglobulin A | 1 | 2015 | 174 | 0.120 |
Why?
| | Internship and Residency | 1 | 2023 | 1001 | 0.120 |
Why?
| | Vaccines | 1 | 2019 | 380 | 0.120 |
Why?
| | Guanine Nucleotide Exchange Factors | 1 | 2014 | 59 | 0.120 |
Why?
| | Cerebrovascular Disorders | 1 | 2014 | 86 | 0.110 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 827 | 0.110 |
Why?
| | Mass Screening | 2 | 2017 | 1052 | 0.110 |
Why?
| | Immunologic Memory | 1 | 2015 | 313 | 0.110 |
Why?
| | Picornaviridae Infections | 1 | 2012 | 29 | 0.110 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2015 | 245 | 0.110 |
Why?
| | Herpesvirus 3, Human | 1 | 2014 | 389 | 0.090 |
Why?
| | Young Adult | 2 | 2015 | 10795 | 0.090 |
Why?
| | Herpes Zoster | 1 | 2014 | 336 | 0.090 |
Why?
| | Female | 11 | 2019 | 61574 | 0.090 |
Why?
| | Adult | 5 | 2021 | 31515 | 0.080 |
Why?
| | Pandemics | 2 | 2020 | 1354 | 0.080 |
Why?
| | Prognosis | 1 | 2016 | 3443 | 0.080 |
Why?
| | Nervous System Diseases | 1 | 2010 | 261 | 0.080 |
Why?
| | Papillomavirus Vaccines | 1 | 2010 | 221 | 0.070 |
Why?
| | Cytokines | 1 | 2015 | 1900 | 0.070 |
Why?
| | Cost-Benefit Analysis | 2 | 2019 | 554 | 0.070 |
Why?
| | Infectious Disease Medicine | 1 | 2023 | 10 | 0.060 |
Why?
| | Accreditation | 1 | 2023 | 87 | 0.060 |
Why?
| | Parents | 1 | 2010 | 1212 | 0.050 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2010 | 1185 | 0.050 |
Why?
| | Incidence | 2 | 2019 | 2424 | 0.050 |
Why?
| | Microbiology | 1 | 2021 | 19 | 0.050 |
Why?
| | Immunization, Secondary | 1 | 2021 | 85 | 0.050 |
Why?
| | Staining and Labeling | 1 | 2021 | 146 | 0.050 |
Why?
| | Critical Pathways | 1 | 2020 | 79 | 0.040 |
Why?
| | Follow-Up Studies | 2 | 2020 | 4596 | 0.040 |
Why?
| | United States | 3 | 2021 | 12554 | 0.040 |
Why?
| | Needs Assessment | 1 | 2020 | 327 | 0.040 |
Why?
| | Information Dissemination | 1 | 2020 | 210 | 0.040 |
Why?
| | Age Factors | 2 | 2019 | 2995 | 0.040 |
Why?
| | Interprofessional Relations | 1 | 2020 | 261 | 0.040 |
Why?
| | Morbidity | 1 | 2019 | 296 | 0.040 |
Why?
| | Models, Econometric | 1 | 2017 | 34 | 0.040 |
Why?
| | Administration, Intravenous | 1 | 2018 | 136 | 0.040 |
Why?
| | Allografts | 1 | 2018 | 135 | 0.040 |
Why?
| | Quality-Adjusted Life Years | 1 | 2017 | 103 | 0.040 |
Why?
| | Markov Chains | 1 | 2017 | 118 | 0.040 |
Why?
| | Patient Isolation | 1 | 2017 | 19 | 0.040 |
Why?
| | Ophthalmoscopy | 1 | 2016 | 30 | 0.040 |
Why?
| | Epidemiological Monitoring | 1 | 2017 | 49 | 0.040 |
Why?
| | Bacteriological Techniques | 1 | 2017 | 66 | 0.040 |
Why?
| | Clinical Competence | 1 | 2023 | 951 | 0.040 |
Why?
| | Gastrointestinal Diseases | 1 | 2018 | 187 | 0.030 |
Why?
| | Program Evaluation | 1 | 2020 | 845 | 0.030 |
Why?
| | North America | 1 | 2016 | 266 | 0.030 |
Why?
| | Intensive Care Units, Pediatric | 1 | 2016 | 157 | 0.030 |
Why?
| | Transplantation, Homologous | 1 | 2016 | 415 | 0.030 |
Why?
| | Hematologic Neoplasms | 1 | 2016 | 133 | 0.030 |
Why?
| | Viral Load | 1 | 2016 | 419 | 0.030 |
Why?
| | Survival Rate | 1 | 2019 | 1720 | 0.030 |
Why?
| | Cost of Illness | 1 | 2016 | 258 | 0.030 |
Why?
| | Antibodies, Neutralizing | 1 | 2016 | 228 | 0.030 |
Why?
| | Disease Outbreaks | 1 | 2016 | 322 | 0.030 |
Why?
| | Anti-Bacterial Agents | 1 | 2022 | 1510 | 0.030 |
Why?
| | Quality Improvement | 1 | 2020 | 963 | 0.030 |
Why?
| | Rhinovirus | 1 | 2012 | 40 | 0.030 |
Why?
| | DNA Mutational Analysis | 1 | 2014 | 381 | 0.030 |
Why?
| | Risk Factors | 2 | 2019 | 9001 | 0.030 |
Why?
| | Enterovirus | 1 | 2012 | 72 | 0.030 |
Why?
| | Inpatients | 1 | 2015 | 389 | 0.030 |
Why?
| | Logistic Models | 1 | 2016 | 1901 | 0.030 |
Why?
| | Critical Illness | 1 | 2016 | 663 | 0.020 |
Why?
| | Infant | 2 | 2016 | 8293 | 0.020 |
Why?
| | Los Angeles | 1 | 2010 | 60 | 0.020 |
Why?
| | Parental Consent | 1 | 2010 | 23 | 0.020 |
Why?
| | Cohort Studies | 2 | 2010 | 5115 | 0.020 |
Why?
| | Risk Assessment | 1 | 2019 | 3057 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2021 | 4708 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2016 | 2674 | 0.020 |
Why?
| | Seasons | 1 | 2010 | 461 | 0.020 |
Why?
| | Uterine Cervical Neoplasms | 1 | 2010 | 216 | 0.020 |
Why?
| | Papillomavirus Infections | 1 | 2010 | 265 | 0.020 |
Why?
| | Critical Care | 1 | 2010 | 492 | 0.020 |
Why?
| | Prevalence | 1 | 2012 | 2326 | 0.020 |
Why?
| | Oxygen | 1 | 2010 | 854 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2016 | 4552 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2016 | 5255 | 0.020 |
Why?
| | Antiviral Agents | 1 | 2010 | 654 | 0.020 |
Why?
| | Time Factors | 1 | 2015 | 6414 | 0.020 |
Why?
| | Patient Acceptance of Health Care | 1 | 2010 | 687 | 0.020 |
Why?
| | Middle Aged | 2 | 2016 | 27623 | 0.010 |
Why?
| | Mutation | 1 | 2014 | 3457 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2014 | 3174 | 0.010 |
Why?
| | Brain | 1 | 2014 | 2490 | 0.010 |
Why?
| | Aged | 1 | 2010 | 19657 | 0.010 |
Why?
|
|
Curtis's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|